MellingMedical, a US-based company that provides veterans with access to healthcare, announced on Wednesday a new strategic relationship with CellTivity Scientific, a US-based company involved in point-of-care disease detection and cellular imaging solutions.
As part of its new relationship, MellingMedical says that it will leverage its status as an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to bring CellTivity's Van Gogh Microscopy System to federal healthcare providers serving America's veterans, active-duty military personnel, and their families.
The arrangement makes CellTivity's Van Gogh Microscopy System immediately available to veterans through MellingMedical's federal contracting network.
The agreement encompasses CellTivity's Van Gogh Microscopy System, an FDA Class I in-vitro diagnostic medical device powered by Dynamic Cell Imaging (DCI). This technology is claimed to allow proceduralists to assess freshly excised biopsies in real time, akin to a tissue-based PET scan, digitally measuring intracellular, and metabolic activity up to 150µm below the tissue surface. This process requires no cutting or staining, leaving 100% of the sample unchanged and perfectly preserved for definitive pathology and downstream molecular analysis.
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test